01Role and principlesWho benefits and the main preventive aims.
Contraceptive counselling starts with the person’s priorities: avoiding pregnancy, spacing, reversibility, bleeding control, privacy, hormone preference, procedure tolerance and protection from infections. Effectiveness depends on both method biology and use. Long-acting methods minimise user action, while pills, patches, rings and barriers place different demands on memory, access and partner cooperation.
UKMEC is a safety framework, not a prescription algorithm. Category 3 does not mean an automatic legal ban; it means risks usually exceed benefits and use needs careful judgement when more appropriate methods are unavailable or unacceptable. Category 4 represents unacceptable health risk. These categories must be paired with product instructions, interaction resources and method-specific guidance.
Counselling remains valid only if it includes what the method does not do. Most contraceptives do not prevent STIs. Hormonal methods can alter bleeding without making every change benign. LARC insertion has procedural risks. Sterilisation is intended to be permanent. A patient can choose a less effective method after informed discussion, and may stop or switch without having to justify the decision.
Key points
- UKMEC 1 means no restriction; 2 means advantages generally outweigh theoretical or proven risks; 3 means risks usually outweigh advantages and specialist judgement plus alternatives are needed; 4 means an unacceptable health risk and the method should not be used.
- UKMEC classifies safety for contraceptive use. It does not select the best method, measure efficacy, account for drug interactions or malabsorption, or provide starting and missed-method instructions.
- Assess pregnancy intention, timing, bleeding goals, STI protection, medical and family history, blood pressure where relevant, smoking, migraine aura, postpartum state, medicines, adherence preferences and ability to stop or remove a method.
- Current migraine with aura at any age is UKMEC 4 for combined hormonal contraception; a history of aura at least five years ago is category 3. Progestogen-only and intrauterine methods have different classifications.
- For CHC, smoking at age 35 or older is category 3 below 15 cigarettes daily and category 4 at 15 or more; blood pressure 140–159/90–99 or adequately controlled hypertension is category 3, while at least 160/100 or vascular disease is category 4.
- Enzyme-inducing medicines can reduce CHC, POP and implant effectiveness. DMPA, LNG-IUD and copper IUD effectiveness is not reduced; use interaction guidance as well as UKMEC.
- Category must be applied to the exact method and current characteristic. Multiple category-2 factors acting through the same risk can justify a more cautious clinical judgement.
02Assessment and patient selectionRisk features, eligibility and important cautions.
The acceptable chance of pregnancy and consequences of failure determine how strongly effectiveness and user dependence influence the choice.
Migraine aura, smoking from age 35, hypertension, VTE history and early postpartum state require exact CHC classification.
Enzyme induction, lamotrigine and medicines with teratogenic potential require contraceptive and reciprocal drug-effect review.
Heavy menstrual bleeding, dysmenorrhoea, amenorrhoea preference and tolerance of irregular bleeding can change which eligible method fits best.
Private discussion may reveal reproductive coercion, adherence barriers, confidentiality needs or a desire for a method hidden from others.
03Baseline assessmentMeasurements that guide the plan and track progress.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Focused medical and medicine historyFirst step - Why
- Identify UKMEC conditions, interactions, postpartum state and non-contraceptive treatment goals.
- Interpretation and limitations
- Use exact diagnoses and current status; vague labels such as headache or clotting problem cannot support a reliable category.
- 02
Blood pressure before CHC - Why
- Classify hypertension-related CHC safety and establish a monitoring baseline.
- Interpretation and limitations
- A single unexpected reading should be repeated correctly, but severe hypertension is not bypassed by choosing patch or ring.
- 03
Pregnancy assessment - Why
- Decide whether pregnancy can be reasonably excluded and whether emergency contraception is required.
- Interpretation and limitations
- A negative test can be too early after intercourse; quick-starting needs a dated follow-up test and backup instructions.
- 04
BMI when method relevant - Why
- Inform CHC VTE classification, emergency-contraception discussion, procedural planning and DMPA counselling.
- Interpretation and limitations
- Weight alone should not block contraception; apply the method-specific evidence and avoid transferring one threshold to every method.
- 05
STI risk and site-based testing - Why
- Offer testing, condoms and vaccination independently of contraceptive method.
- Interpretation and limitations
- An IUD does not cause an STI, but insertion during active gonorrhoea or chlamydia requires matched management.
04InterventionsLifestyle, treatment and escalation options.
01Shared-choice pathwayStart with goals before method labelsFirst stepA person asks for contraception without having selected a method.+
- 1Clarify pregnancy intentions, desired duration, effectiveness priority, bleeding preference, privacy, reversibility and STI prevention.
- 2Screen medical eligibility and medicines, then present all suitable methods with typical-use demands, benefits, common adverse effects and serious warning symptoms.
- 3Agree initiation, backup, missed-method, follow-up and switching instructions in a format the person can use.
02UKMEC pathwayTranslate category into a safe decisionA characteristic may alter the safety of one or more contraceptive methods.+
- 1Name the exact condition and method, then check the current UKMEC 2025 row rather than relying on a remembered older table.
- 2Treat category 1 as unrestricted, 2 as generally favourable, 3 as generally unfavourable requiring careful judgement, and 4 as do not use.
- 3Add efficacy, interaction, product, indication and patient-preference evidence because UKMEC does not answer those questions.
03Quick-start pathwayPrevent delay after recent riskPregnancy cannot yet be excluded or recent unprotected intercourse may need emergency contraception.+
- 1Assess copper IUD and oral emergency-contraception eligibility using intercourse and ovulation timing.
- 2Start the chosen ongoing method at the correct interval after LNG or UPA, explain backup and account for enzyme-inducing drugs.
- 3Arrange a pregnancy test at the appropriate interval after the latest unprotected sex and give ectopic and pregnancy safety-net advice.
05Medicines and treatment safetyRegimens, contraindications and review points.
Combined hormonal contraception
Use the licensed daily pill, weekly patch or vaginal-ring schedule, including a standard or evidence-based tailored hormone-free interval selected for that formulation.Check migraine aura, smoking from age 35, blood pressure, BMI, VTE and arterial risk, postpartum state, liver disease, breast cancer and interacting medicines.
Progestogen-only and intrauterine options
Use the formulation-specific POP schedule, DMPA interval, implant duration or device duration; instructions are not interchangeable within the class.Current breast cancer, unexplained bleeding, infection or uterine anatomy, enzyme induction and product-specific duration require separate assessment. Enzyme induction can reduce CHC, POP and implant effectiveness; copper IUD, LNG-IUD and DMPA effectiveness is not reduced.
06Targets, monitoring and follow-upResponse, safety and longer-term review.
- Review satisfaction, bleeding, adherence, new diagnoses, smoking, migraine, blood pressure where relevant and medicine changes at a method-appropriate interval.
- Teach method-specific warning symptoms and give a direct route for urgent assessment rather than relying on a routine renewal appointment.
- At every interacting-medicine change, reassess both contraceptive effectiveness and whether contraception changes the other drug, including lamotrigine.
- Track removal or replacement dates using the exact product, dose, insertion age and indication, since contraceptive and therapeutic durations can differ.
- Offer condoms, STI testing, vaccination and reproductive-intention review independently of the chosen contraceptive.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Eligibility is not efficacy
A method can be medically safe yet unreliable with enzyme induction, vomiting, malabsorption or missed use.
Route does not erase oestrogen
Combined patch and ring share CHC vascular classifications even though they bypass oral absorption.
One device has several clocks
An LNG-IUD can have different durations for contraception, heavy menstrual bleeding and endometrial protection.
Category three needs context
It signals that risk usually exceeds benefit and calls for alternatives and expert judgement rather than a casual supply decision.
Choice includes stopping
Consent continues after initiation; a person can request removal or switch even when the method remains medically suitable.
08Common pitfallsFrequent interpretation and management errors.
- 01
Using UKMEC 2016 when UKMEC 2025 is available.
- 02
Calling category 2 completely risk free or category 3 an absolute category 4 prohibition.
- 03
Forgetting interactions because the method is medically eligible.
- 04
Applying one missed-pill or duration rule to every formulation.
- 05
Discussing pregnancy prevention without STI protection, coercion or reproductive goals.